SEC Form 4 · accession 0001209191-16-148867
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer J Rhodes
Officer — General Counsel
Period of report
Nov 7, 2016
Accepted (ET)
Nov 8, 2016 · 4:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 7, 2016 | A | 4,687 | $0.00 | A | 15,937 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $14.26 | Nov 7, 2016 | A | 28,125 | A | — | Nov 6, 2026 | Common Stock | 28,125 | 28,125 | D |
Explanation of responses
- F1Represents the grant of restricted stock units that vest 1/4th on each of December 20, 2017, December 20, 2018, December 20, 2019, and December 20, 2020.
- F2The shares subject to the option shall become vested according to the following schedule: 25% of the shares subject to the option shall vest on October 29, 2017, and the remaining shares will vest in equal monthly installments over the next 36 months.